Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Assets Average (2016 - 2025)

Cardiff Oncology's Assets Average history spans 14 years, with the latest figure at $62.8 million for Q4 2025.

  • For Q4 2025, Assets Average fell 21.5% year-over-year to $62.8 million; the TTM value through Dec 2025 reached $62.8 million, down 21.5%, while the annual FY2025 figure was $79.5 million, 11.05% down from the prior year.
  • Assets Average for Q4 2025 was $62.8 million at Cardiff Oncology, down from $69.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $145.4 million in Q4 2021 and bottomed at $62.8 million in Q4 2025.
  • The 5-year median for Assets Average is $97.5 million (2023), against an average of $103.6 million.
  • The largest annual shift saw Assets Average soared 961.36% in 2021 before it tumbled 31.33% in 2024.
  • A 5-year view of Assets Average shows it stood at $145.4 million in 2021, then decreased by 17.55% to $119.9 million in 2022, then fell by 29.08% to $85.0 million in 2023, then decreased by 5.88% to $80.0 million in 2024, then dropped by 21.5% to $62.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Assets Average are $62.8 million (Q4 2025), $69.8 million (Q3 2025), and $80.3 million (Q2 2025).